Announcements Trials
Browse Landscape

Phase

Phase 2/3 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Leukemia, Myeloid, Acute 6Hematologic Neoplasms 2Recurrence 1Prostatic Neoplasms 1Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Myelodysplastic Syndromes 1Lymphoma, Non-Hodgkin 1Lymphoma, Large B-Cell, Diffuse 1Leukemia, Biphenotypic, Acute 1

Interventions

Cyclophosphamide 22Dexamethasone 15Cytarabine 15venetoclax 14Vincristine 13Methotrexate 10Etoposide 10Prednisone 9Doxorubicin 9Calcium Dobesilate 9prednylidene 8dexamethasone acetate 8dexamethasone 21-phosphate 8deltacortene 8auricularum 8merphos 7Specimen Handling 7pegaspargase 6fludarabine phosphate 6daratumumab 6calaspargase pegol 6Mercaptopurine 6Granulocyte Colony-Stimulating Factor 6fludarabine 5Stem Cell Transplantation 5Filgrastim 5Daunorubicin 5Bortezomib 5Biopsy 5Azacitidine 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma × Homoharringtonine × 1 year × Clear all
NCT06855810 2025-08-26

CCCG-TALL-2025

Institute of Hematology & Blood Diseases Hospital, China

Phase 2/3 Recruiting
610 enrolled
LymphoidOther hematologic neoplasm

Precursor Cell Lymphoblastic Leukemia-Lymphoma, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡